<SEC-DOCUMENT>0001493152-22-019965.txt : 20220721
<SEC-HEADER>0001493152-22-019965.hdr.sgml : 20220721
<ACCEPTANCE-DATETIME>20220721083534
ACCESSION NUMBER:		0001493152-22-019965
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220619
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220721
DATE AS OF CHANGE:		20220721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProPhase Labs, Inc.
		CENTRAL INDEX KEY:			0000868278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				232577138
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21617
		FILM NUMBER:		221095639

	BUSINESS ADDRESS:	
		STREET 1:		711 STEWART AVE, SUITE 200
		STREET 2:		GARDEN CITY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			11530
		BUSINESS PHONE:		(215) 345-0919

	MAIL ADDRESS:	
		STREET 1:		711 STEWART AVE, SUITE 200
		STREET 2:		GARDEN CITY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			11530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QUIGLEY CORP
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:PRPH="http://prophaselabs.com/20220619">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_PRPH_prophaselabs.com_20220619 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20220619_20220619 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000868278 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityCentralIndexKey">0000868278</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="prph-20220619.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-06-19to2022-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-19</xbrli:startDate>
        <xbrli:endDate>2022-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20220619__20220619_zT5cDmD67C4b"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-top: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_90F_edei--DocumentPeriodEndDate_c20220619__20220619_z18tS8mb1KG6"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 19, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20220619__20220619_zxn0csC6me93"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityRegistrantName">PROPHASE
LABS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Company as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20220619__20220619_zCxsyTsOSVq5"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20220619__20220619_zaB3OFnBnvDe"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityFileNumber">000-21617</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20220619__20220619_zQQxYlR8eSG2"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityTaxIdentificationNumber">23-2577138</ix:nonNumeric></span>
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">jurisdiction
    of incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220619__20220619_z0xOLbHkrpIb"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityAddressAddressLine1">711
                                            Stewart Avenue</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20220619__20220619_zkMv9rgcoBH9"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220619__20220619_zMw9KZG8FcCe"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityAddressCityOrTown">Garden
    City</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220619__20220619_zE7wZ5TjKp8k"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20220619__20220619_zHGaCU1HwiL2"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:EntityAddressPostalZipCode">11530</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s
telephone number, including area code: <b><span id="xdx_90C_edei--CityAreaCode_c20220619__20220619_z1MqKksn0iw1"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:CityAreaCode">(215)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20220619__20220619_zHepcRq73iv"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:LocalPhoneNumber">345-0919</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (<i>see</i> General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20220619__20220619_zmyuAyph6uCh"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20220619__20220619_zdPIaXKDVKn3"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20220619__20220619_zGqsUtjgo5z2"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220619__20220619_z30BOGyi7wf1"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Registered Pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Each Exchange on Which Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20220619__20220619_z7wfwBXbsSsg"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:Security12bTitle">Common
    Stock, par value $0.0005</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220619__20220619_zg34tPNDN4Of"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" name="dei:TradingSymbol">PRPH</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_909_edei--SecurityExchangeName_c20220619__20220619_znDZm4Dh4jz3"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220619__20220619_zIibJQ1koiHk"><ix:nonNumeric contextRef="From2022-06-19to2022-06-19" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&amp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, ProPhase BioPharma, Inc. (&#8220;ProPhase BioPharma&#8221;), a wholly-owned subsidiary of ProPhase Labs, Inc. (the &#8220;Company&#8221;),
entered into a License Agreement (the &#8220;License Agreement&#8221;) with Global BioLife, Inc. (the &#8220;Licensor&#8221;), with an
effective date of July 18, 2022 (the &#8220;Effective Date&#8221;), pursuant to which it acquired from Licensor a worldwide exclusive
right and license under certain patents identified in the License Agreement (the &#8220;Licensed Patents&#8221;) and know-how (collectively,
the &#8220;Licensed IP&#8221;) to exploit any compound covered by the Licensed Patents (the &#8220;Licensed Compound&#8221;), including
Linebacker LB1 and LB2, and any product comprising or containing a Licensed Compound (&#8220;Licensed Products&#8221;) in the treatment
of cancer, inflammatory diseases or symptoms, memory-related syndromes, diseases or symptoms including dementia and Alzheimer&#8217;s
Disease (the &#8220;Field&#8221;). Under the terms of the License Agreement, the Licensor reserves the right, solely for itself and for
GRDG Sciences, LLC (&#8220;GRDG&#8221;) to use the Licensed Compound and Licensed IP solely for research purposes inside the Field and
for any purpose outside the Field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain conditions set forth in the License Agreement, ProPhase BioPharma may grant sublicenses (including the right to grant further
sublicenses) to its rights under the License Agreement to any of its affiliates or any third party with the prior written consent of
Licensor, which consent may not be unreasonably withheld. Either party to the License Agreement may assign its rights under the License
Agreement (i) in connection with the sale or transfer of all or substantially all of its assets to a third party, (b) in the event of
a merger or consolidation with a third party or (iii) to an affiliate; in each case contingent upon the assignee assuming in writing
all of the obligations of its assignor under the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of License Agreement, ProPhase BioPharma is required to pay to Licensor a one-time upfront license fee of $50,000 within 10
days of the Effective Date and must pay an additional $900,000 following the achievement of a first Phase 3 study which may be required
by FDA for the first Licensed Product and an additional $1 million upon the receipt of regulatory approval of a New Drug Application
(NDA) for the first Licensed Product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Term, ProPhase BioPharma is also required to pay to Licensor 3% royalties on Net Revenue (as defined in the License Agreement) of
each Licensed Product, but no less than the minimum royalty of $250,000 of Net Revenue per year minus any royalty payments for any required
third party licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the License Agreement, the development of the Licensed Compound and the first Licensed Product for the United States will
be governed by a clinical development plan, including anticipated timeline goals in connection with the clinical trials for the first
Licensed Product (the &#8220;Development Plan&#8221;). The Development Plan may be amended by the mutual written agreement of the parties
to the License Agreement based upon results of preclinical studies or clinical trials, including safety and effectiveness, guidance by
the FDA, or upon the agreement of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement will expire automatically on a country-by-country basis upon the last to occur of the expiration of the last to expire
Licensed Patents (the &#8220;Term&#8221;). Following the expiration of the Term, and on a country-by-country basis, the License will
become non-exclusive, perpetual, fully-paid, unrestricted, royalty-free and irrevocable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement may be terminated by ProPhase BioPharma for any reason or for convenience in its sole discretion: (i) on a Licensed
Product-by-Licensed Product or a country-by-country basis or (ii) in its entirety, in either case ((i) or (ii)) for convenience upon
180 days prior written notice to Lessor. Lessor may terminate the License Agreement solely for a material breach of the License Agreement
by ProPhase BioPharma, which is not cured within 60 days&#8217; of written notice to ProPhase BioPharma of such breach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
    FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Company issued a press release announcing the License Agreement and other matters. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously announced on July 19, 2022, the Company will host a webcast on July 21, 2022 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific
Time to review the latest developments at the Company and its subsidiaries, including the License Agreement described in Item 1.01 of
this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has posted a presentation to be used during the webcast on its website at https://ir.prophaselabs.com/company-information/presentations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presentation referred to above contains or may contain forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). Actual results and developments may differ materially from the expectations expressed in or implied by such forward-looking
statements because of risks and uncertainties, including the risks and uncertainties described in the press release described above,
in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2021 and in its subsequent reports on Form 10-Q and
Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information included in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the Securities Exchange Act, nor shall it be incorporated by reference in any registration statement filed under the
Securities Act, unless specifically identified therein as being incorporated by reference therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01 </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="ex10-1.htm">License Agreement by and between ProPhase BioPharma, Inc. and Global BioLife, Inc., dated July 19, 2022 (effective as of July 18, 2022)</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><a href="ex99-1.htm">Press Release dated July 21, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase
    Labs, Inc. </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bill White</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill White</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
July 21, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LjUNFqGPFhWxihQRX6NdJdhmyyb+HclbGlvEZWFZZr4ZIWKxoLlpkOEwrUrYYds12iNUeEZGe8LgKJarHMKt8GKcZ219//7AggKDgcmSNDsGobfejcM6BzkZKTlSCuQ4zyRs1yL66gXZs6nReqMb0LaGLVPHBr3m15Cw00+y1L76qj2yM2RzSBM5yG9QMlWwobt+EF8dlGUhorifSCyYbt235uY8tTBrsA1dbkD/G30AGBhJSQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Exhibit
10.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LICENSE
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
LICENSE AGREEMENT (the &ldquo;<U>Agreement</U>&rdquo;), made and effective as of July 18, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;),
is by and between ProPhase BioPharma, Inc. (&ldquo;<U>ProPhase</U>&rdquo;), a corporation organized and existing under the laws of the
State of Delaware, having its principal office at 711 Stewart Ave, Suite 200, Garden City, NY, 11530 and Global BioLife, Inc. (&ldquo;Global
BioLife&rdquo; or &ldquo;<U>Licensor</U>&rdquo;), a corporation organized and existing under the laws of the State of Nevada, having
its principal office at 1400 Broadfield Blvd., Suite 100, Houston, Texas 77084. Each of ProPhase and Licensor are referred to herein
as a &ldquo;<U>Party</U>&rdquo; and collectively as the &ldquo;<U>Parties.</U>&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Licensor owns certain intellectual property rights directed to the Licensed Compound (as defined below); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
ProPhase wishes to obtain, and Licensor wishes to grant, a license to these certain intellectual property rights of Licensor for the
purpose of Exploiting (as defined below) the Licensed Compound and Licensed Products (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and agreements contained herein, the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>1. <U>DEFINITIONS.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01 &ldquo;<U>Action</U>&rdquo;
has the meaning set forth in Section 8.02.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02 &ldquo;<U>Affiliate</U>&rdquo;
means any company or other legal entity in which a Party holds at least fifty percent (50%) of (i) the capital or (ii) the voting rights
..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03 &ldquo;<U>Agreement</U>&rdquo;
has the meaning set forth in the introductory paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.04 &ldquo;<U>Calendar
Year</U>&rdquo; means any consecutive period of twelve months commencing on the first day of January of any year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.05 <U>&ldquo;Clinical
Trial</U>&rdquo; means a Phase 1 Study, a Phase 2 Study, a Phase 3 Study, a Phase 4 Study, or a combination of two (2) or more of any
of the foregoing studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.06 &ldquo;<U>Combination
Product</U>&rdquo; means a Licensed Product that is comprised of or contains Licensed Compound as an active ingredient together with
one (1) or more different active ingredients, whether in the same or different formulations and is sold either (i) as a fixed dose unit
at a single price, or (ii) sold in separate doses as one (1) product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.07 &ldquo;<U>Commercially
Reasonable Efforts</U>&rdquo; means, with respect to ProPhase&rsquo;s obligations under <U>Section 5.01</U>, the carrying out of such
obligations by ProPhase using efforts and resources comparable to the efforts and resources that ProPhase would typically devote to a
product of similar market potential at a similar stage of in development or product life, taking into consideration all relevant scientific,
commercial, and other factors that ProPhase would take into account, including, without limitation, issues of safety and efficacy, expected
and actual product labelling, expected and actual time to develop, the nature and extent of expected and actual market exclusivity (including
Patent coverage), expected and actual profitability (including royalties and other payments required hereunder), expected and actual
competitiveness of alternative products, and the expected and actual amounts of marketing and promotional expenditures required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.08 &ldquo;<U>Infringing
Product</U>&rdquo; has the meaning set forth in Section 8.02.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09 &ldquo;<U>Confidential
Information</U>&rdquo; means (a) all confidential or proprietary information relating to the Licensed Compound and Licensed Products,
and (b) all other confidential or proprietary documents, technology, Know-How, or other information (whether or not patentable) actually
disclosed by or on behalf of one Party to the other or its representatives pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10 &ldquo;<U>Control</U>&rdquo;
or &ldquo;<U>Controlled</U>&rdquo; means, with respect to any (a) material, document, item of information, method, data, or other Know-How,
or (b) Patent Rights or other Intellectual Property Rights, the possession by a Party or its Affiliates, whether by ownership or license
(other than by licenses granted under this Agreement), of the ability to grant to the other Party access, a license and/or a sublicense
as provided herein without requiring the consent of a Third Party or violating the terms of any agreement or other arrangement with any
Third Party, in each case as of the Effective Date, or if any of the same are acquired or created after the Effective Date, at the date
it is acquired or created by the relevant Party or its Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11 &ldquo;<U>Commercialization</U>&rdquo;
or &ldquo;<U>Commercialize</U>&rdquo; means any activities directed to obtaining Pricing and Reimbursement Approval, marketing, promoting,
distributing, importing, exporting, Detailing, offering to sell, and/or selling a Licensed Product (including establishing the price
for such product).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12 &ldquo;<U>Cover</U>&rdquo;,
&ldquo;<U>Covering</U>&rdquo;, or &ldquo;<U>Covered</U>&rdquo; means, with respect to a Licensed Product, the Exploitation of or manufacturing
of the Licensed Product, is encompassed within a valid claim of one or more Licensed Patents (or, in the case of an application that
that has not yet issued, would infringe a claim of the application if it were to issue as a patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13 &ldquo;<U>Date
of First Commercial Sale</U>&rdquo; means the date on which a Licensed Product is first sold for monetary value for use or consumption
by the end user of such Licensed Product by ProPhase, its Affiliate or its Sublicensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14 &ldquo;<U>Development</U>&rdquo;
or &ldquo;<U>Develop</U>&rdquo; means, with respect to the Licensed Compound and Licensed Product, those activities necessary or useful
for research and development, including: preclinical and clinical drug development activities, the conduct of Clinical Trials, test method
development and stability testing, toxicology, formulation, and delivery system development, process development, pre-clinical and clinical
Licensed Compound and Licensed Product supply, manufacturing scale-up, development-stage manufacturing, quality assurance/quality control
procedure development, and performance with respect to clinical materials, statistical analysis, and report writing, and clinical studies,
and regulatory affairs. When used as a verb, &ldquo;<U>Develop</U>&rdquo; means to engage in Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15 &ldquo;<U>Disclosing
Party</U>&rdquo; means, with respect to Confidential Information, Patent Rights, or Know-How, the Party that owns or Controls such Confidential
Information, Patent Rights, or Know-How.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16 &ldquo;<U>Effective
Date</U>&rdquo; has the meaning set forth in the introductory paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17 &ldquo;<U>Exploit</U>&rdquo;
&ldquo;<U>Exploiting</U>&rdquo;, or &ldquo;<U>Exploitation</U>&rdquo; would mean to make, have made, import, use, sell, or offer for
sale, including to research, develop, Commercialize, register, modify, enhance, improve, manufacture, have manufactured, hold or keep
(whether for disposal or otherwise), formulate, optimize, have used, export, transport, distribute, promote, market, have sold or otherwise
dispose of.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18 &ldquo;<U>FDA</U>&rdquo;
means the United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19 &ldquo;<U>Field</U>&rdquo;
means all uses limited to modified phenolic compounds relating to the treatment of cancer, inflammatory diseases or symptoms, memory-related
syndromes, diseases or symptoms, including dementia and Alzheimer&rsquo;s Disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20 &ldquo;GRDG&rdquo;
means GRDG Sciences, LLC, a company organized in the state of Florida with a principal business office address of 234 W. Central Ave.,
Winter Haven, Florida 33880</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21 &ldquo;<U>IND</U>&rdquo;
means an Investigational New Drug Application filed with the FDA under 21 C.F.R. Part 312 or similar non-United States application or
submission in any country or group of countries for permission to conduct human clinical investigations, including all supplements, amendments,
variations, extensions, and renewals <U>thereof</U> that may be filed with respect to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22 &ldquo;<U>Indemnitees</U>&rdquo;
has the meaning set forth in <U>Section 9.02</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23 &ldquo;<U>Indemnitor</U>&rdquo;
has the meaning set forth in <U>Section 9.03</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24 &ldquo;<U>Intellectual
Property Rights</U>&rdquo; means: (a) Know-How; (b) Patent Rights; (c) original works, copyrights, moral rights, and mask-works; (d)
trademarks, trade dress, and similar rights based on designation; (e) utility models, designs, and other industrial property rights;
and (f) any other forms of proprietary or industrial rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25 &ldquo;<U>Inventions</U>&rdquo;
means all Intellectual Property Rights that are discovered, made, or conceived by either Party (or both Parties) or any of its Affiliates,
GRDG or Sublicensees, or any of the foregoing Person&rsquo;s employees, independent contractors, or consultants in the course of conducting
activities under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26 <U>&ldquo;Know-How</U>&rdquo;
means any information, ideas, data, works of authorship, trade secrets, practices, techniques, procedures, knowledge, skill, experience,
or materials, including formulations, molecules, assays, reagents, compounds, biologic molecules, compositions, methods of treatment,
and/or use thereof, human or animal tissue, samples, or specimens, and combinations or components thereof, whether or not proprietary
or patentable, or public or confidential, and whether stored or transmitted in oral, documentary, electronic, or other form, including
all Regulatory Documentation, but excluding any such information or materials publicly disclosed in Patent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27 &ldquo;<U>Knowledge</U>&rdquo;
means a particular fact or other matter that is actually known to a Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28 &ldquo;<U>Law</U>&rdquo;
means any law, statute, rule, regulation, ordinance, or other pronouncement having the effect of law, of any federal, national, multinational,
state, provincial, county, city, or other political subdivision, including (a) good clinical practices and adverse event reporting requirements,
guidance from the International Conference on Harmonization or other generally accepted conventions, and all other rules, regulations
and requirements of the FDA and other applicable Regulatory Authorities, (b) the Foreign Corrupt Practices Act of 1977, as amended, or
any comparable laws in any country, and (c) all export control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29 &ldquo;<U>Licensed
Compound</U>&rdquo; means any compound covered by one or more claims in the Licensed Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30 &ldquo;<U>Licensed
IP</U>&rdquo; means the Licensed Patents and the Licensed Know-How.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31 &ldquo;<U>Licensed
Know-How</U>&rdquo; means all Know-How owned or Controlled by Licensor, Licensor&rsquo;s Affiliates, and GRDG as of the Effective Date
and learned during the Term that is necessary or useful for the Exploitation of the Licensed Compound and/or any Licensed Product in
the Field in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32 &ldquo;<U>Licensed
Patent(s)</U>&rdquo; means any Patents (including without limitation any Patents that cover Global BioLife&rsquo;s interest in any Joint
Inventions) owned or Controlled by, or otherwise comes into the Control of, Global BioLife or any of its Affiliates at any time during
the Term that Cover or otherwise claim the Licensed Compound or Licensed Product or necessary for the Exploitation of the Licensed Product.
The Global BioLife Patents that exist as of the Effective Date shall be set forth on an Appendix 1 and Appendix II but the patent application
of Appendix II is limited to patent claims covering monochlorinated myricetin and dichlorinated myricetin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33 &ldquo;<U>Licensed
Product(s)</U>&rdquo; means any product comprising or containing a Licensed Compound, alone or in combination with one or more other
active ingredients in any and all forms, in current and future formulations, dosage forms and strengths, and delivery modes. For clarity,
a Licensed Product that contains the same Licensed Compound, but is in a different form, dosage, formulation, strength, presentation
or delivery mode would be considered the same Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34 &ldquo;<U>Licensor</U>&rdquo;
has the meaning set forth in the introductory paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35 &ldquo;<U>Licensor
Indemnitees</U>&rdquo; has the meaning set forth in <U>Section 9.01</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36 &ldquo;<U>NDA</U>&rdquo;
means (a) (i) a New Drug Application submitted to the FDA, or any successor application or procedure, as more fully defined in 21 C.F.R.
&sect; 314.50 et seq., or (ii) any non-United States counterpart of such a New Drug Application, and (b) all supplements and amendments,
including supplemental New Drug Applications (and any non-United States counterparts) that may be filed with respect to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37 &ldquo;<U>Net
Revenue</U>&rdquo; means the gross revenue invoiced in connection with sales of the Licensed Products to any person or entity that is
not an Affiliate or a Sublicensee of ProPhase under the License, after deduction of all the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) expenses
directed to shipping, such as freight, insurance, import/export fees and other transportation charges to the extent added to the sale
price and set forth separately as such in the total amount invoiced;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) taxes
on sales and customs and excise duties and other taxes or duties, to the extent added to the sale price and set forth separately as such
in the total amount invoiced;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) typical
credits, discounts, or refunds on returns, including amounts repaid or credited by reason of rejection, defects, return good allowance,
recalls or returns;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) seven
percent (7%) of marketing expenses specifically directed to Licensed Products or portion thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;the portion of administrative fees paid to group purchasing organizations, pharmaceutical benefit managers or Medicare Prescription
Drug Plans directed to such Licensed Product or portion thereof and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) any
royalty payments actually paid to Third Parties that are necessary and required to market Licensed Product in a particular territory
..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Revenue shall be determined on a Licensed Product-by-Licensed Product basis. If ProPhase, its Affiliates or Sublicensees separately sells
in such country, a Combination Product, the Net Revenue attributable to such Combination Product shall include a deduction in the amount
of the lesser of the actual or fair market value of the different active ingredient provided that said amount does not reduce the Net
Revenue received by Global for Licensed Product not sold as a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38 &ldquo;<U>Person</U>&rdquo;
means any natural person, general or limited partnership, corporation, limited liability company, limited liability partnership, firm,
association, or organization or other legal entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39 &ldquo;<U>Phase
1 Study</U>&rdquo; means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers
or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as further defined in
21 C.F.R. &sect; 312.21(a) (or the non-United States equivalent thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40 &ldquo;<U>Phase
2B Study</U>&rdquo; means a controlled dose ranging Phase 2 Study with a sufficient number of patients to generate sufficient safety
and efficacy data to, if successful, commence a Phase 3 Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 <U>&ldquo;Phase
3 Study</U>&rdquo; means a controlled study in humans of the efficacy and safety of a product, which is prospectively-designed to demonstrate
statistically whether such product is effective and safe for use in a particular Indication in a manner sufficient to file an NDA to
obtain Regulatory Approval to market the product, as further defined in 21 C.F.R. &sect; 312.21(c) (or the non-United States equivalent
thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42 &ldquo;<U>Pricing
and Reimbursement Approval</U>&rdquo; means the approval, agreement, determination or decision from a Regulatory Authority establishing
the price and/or reimbursement for Licensed Product for sale in a given country or regulatory jurisdiction of the Territory, as required
by Law in such country or other regulatory jurisdiction prior to or subsequent to the marketing and sale of Licensed Product in such
country or regulatory jurisdiction of the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43 &ldquo;<U>ProPhase</U>&rdquo;
has the meaning set forth in the introductory paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44 &ldquo;<U>Quarter-Year
Report</U>&rdquo; has the meaning set forth in <U>Section 4.03(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45 &ldquo;<U>Regulatory
Approval</U>&rdquo; means all approvals, licenses, registrations, and authorizations of any federal, national, multinational, state,
provincial, or local Regulatory Authority, department, bureau, and other governmental entity that are necessary and sufficient for the
marketing and sale of a product in a country or group of countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46 &ldquo;<U>Regulatory
Authority</U>&rdquo; means any applicable supra-national, federal, national, regional, state, provincial, or local governmental or regulatory
authority, agency, department, bureau, commission, council, or other entities (e.g., the United States Food &amp; Drug Administration)
regulating or otherwise exercising authority with respect to activities contemplated in this Agreement, including the Exploitation of
the Licensed Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47 &ldquo;<U>Regulatory
Documentation</U>&rdquo; means, with respect to the Licensed Compound and Licensed Products, all INDs, NDAs, and other regulatory applications
submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug
dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. &sect; 314.420 and any non-United States equivalents), and
any other reports, records, regulatory correspondence, and other materials relating to Development or Regulatory Approval of the Licensed
Compound or a Licensed Product, or required to manufacture, distribute, or sell the Licensed Products, including any information that
relates to pharmacology, toxicology, chemistry, manufacturing, and controls data, batch records, safety and efficacy, and any safety
database.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48 <U>&ldquo;Right
of Reference</U>&rdquo; means a &ldquo;Right of Reference or Use&rdquo; as that term is defined in 21 C.F.R. &sect; 314.3(b), and any
non-United States equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49
&ldquo;<U>Sublicense</U>&rdquo; has the meaning set forth in <U>Section 2.02</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50 &ldquo;<U>Sublicensee</U>&rdquo;
and &ldquo;<U>Sublicensees</U>&rdquo; have the meanings set forth in <U>Section 2.02</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51 &ldquo;<U>Term</U>&rdquo;
has the meaning set forth in <U>Section 10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52 &ldquo;<U>Territory</U>&rdquo;
means worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53 &ldquo;<U>Third
Party</U>&rdquo; means any Person other than a Party or any of its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54 &ldquo;<U>United
States</U>&rdquo; or &ldquo;<U>U.S.</U>&rdquo; means the United States of America and its territories and possessions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55 <U>Construction</U>.
In construing this Agreement, unless expressly specified otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) references
to Sections and Exhibits are to sections of, and exhibits to, this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;except
where the context otherwise requires, use of either gender includes the other gender, and use of the singular includes the plural and
vice versa;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) headings
and titles are for convenience only and do not affect the interpretation of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;any
list, an example or examples following the word &ldquo;including&rdquo; or &ldquo;includes&rdquo; shall be interpreted without limitation
to the generality of the preceding words;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;except
where the context otherwise requires, the word &ldquo;or&rdquo; is used in the inclusive sense (<I>i.e.</I>, &ldquo;A or B&rdquo; means:
A alone, B alone, or A and B);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) all
references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; herein shall mean United States Dollars; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) each
Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated
in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption
will apply against the Party which drafted such terms and provisions.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>2. <U>GRANT
OF LICENSE</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.01 Subject
to the reservation of rights set forth in Section 2.02, and other terms and conditions herein set forth, Global BioLife hereby grants
to ProPhase an exclusive right and license, with the right to sublicense (in accordance with Section 2.03) under the Licensed IP to Exploit
the Licensed Compound and Licensed Products in the Field in the Territory, and ProPhase hereby accepts the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.02 Global
BioLife reserves the right, solely for itself and for GRDG to use the Licensed Compound and Licensed IP solely for research purposes
in the Field and for any purpose outside the Field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.03 Prophase
may grant sublicenses (including the right to grant further sublicenses) under the License it receives under Section 2.01 to any of its
Affiliates or any Third Party with the prior written consent of Global BioLife, which consent shall not be unreasonably withheld; provided
that: (i) each sublicense is in writing and its terms are consistent with the terms and conditions of this Agreement; (ii) Prophase shall
be responsible to Global BioLife for the performance of its sublicensees; and (iii) any act or omission by a sublicensee that would be
a breach of this Agreement had it been performed (or not performed) by Prophase shall be treated as a breach of this Agreement by Prophase.
Prophase shall remain primarily responsible to Global BioLife for its obligations, including payment obligations pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>3. <U>INFORMATION
TRANSFER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.01 <U>Initial
Information Transfer to Prophase</U>. All information owned by Global BioLife relating to the Licensed Compound in connection with the
Field has been made available to Prophase prior to the Effective Date or is publicaly available from the USPTO web site (www.uspto.gov).
Further information related to the Licensed Compounds is believed to be available from GRDG and Global BioLife has requested that GRDG
share all such information with Prophase.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>4. FINANCIAL
PROVISIONS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.01 License
Fee. In partial consideration of the licenses and rights granted to Prophase hereunder, within ten (10) days after the Effective Date,
Prophase shall pay to Global BioLife a one-time upfront license fee of fifty thousand dollars ($50,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.02 Milestone
Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Development
and Regulatory Milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) In
partial consideration of the rights granted by Global BioLife to Prophase hereunder and subject to the terms and conditions set forth
in this Agreement, Prophase shall pay to Global BioLife a milestone payment according to Section 4.02(b) after the achievement of each
of the following regulatory milestones:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. successful
completion of a first Phase 3 Study which may be required by FDA for the first Licensed Product, nine-hundred thousand dollars ($900,000);
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. Regulatory
Approval of an NDA for the first Licensed Product, one million dollars ($1,000,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Milestone
Payment Procedures</U>. Prophase shall provide Global BioLife with written notice of the achievement of each milestone event within ten
(10) days after achievement of the milestone event set forth in Section 4.02(a). Prophase shall pay to Global BioLife, by wire transfer
to an account designated by Global BioLife, the applicable milestone payment listed above within thirty (30) days after the applicable
notice deadline in this Section 4.02(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.03 <U>Royalties.
</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Royalty</U>.
Prophase shall pay to Global BioLife 3% royalties on Net Revenue of each Licensed Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Royalty
Term</U>. Royalties payable under this Section 4.03 shall be paid by Prophase from the date of First Commercial Sale of each Licensed
Product and for the Term of this Agreement. Any payments due under this <U>Section 4.03</U> shall be subject to any applicable credits
or offsets provided for in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Minimum
Royalty</U>. Notwithstanding Section 4.03 (a) <FONT STYLE="background-color: white">above, </FONT>with respect to sales of Licensed Products
made in countries, Prophase shall pay to Global BioLife no less than two hundred fifty thousand dollars ($250,000) of Net Revenue per
year minus any possible royalty payments actually paid per year to Third Parties that are necessary and required to market Licensed Product
in a particular territory as per Section 1.34 , commencing the first full calendar year after receiving Regulatory Approval by a Regulatory
Authority to Exploit the first Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Royalty
Reports</U>. For the purpose of computing the royalties due to Licensor hereunder, the year shall be divided into four parts ending on
March 31, June 30, September 30, and December 31. Not later than sixty (60) days after the end of each December, March, June, and September
in each Calendar Year, after the Date of First Commercial Sale and during the Term, ProPhase shall submit to Licensor a report of royalties
due Licensor under the terms of this <U>Section 4</U> for the preceding quarter year (hereinafter, the &ldquo;<U>Quarter-Year Report</U>&rdquo;),
setting forth the Net Revenue upon which such royalties are computed. If no royalties are due, no statement shall be sent to Licensor.
Payment of the full amount of any royalties due for the preceding quarter year shall accompany each Quarter-Year Report on royalties.
Prophase shall keep for a period of at least seven (7) years after the date of entry, accurate and compete books and records relating
to Net Revenue consistent with sound business and accounting practices and in such form and in such detail as to enable the determination
of the amounts due to Licensor pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Royalty
Payments</U>. Royalties due to Licensor, if any, shall be paid in United States dollars in conjunction with the submission of each Quarter-Year-Report
and with no deductions for banking, currency conversion charges, wire or other transaction fees.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>5. <U>DEVELOPMENT
AND COMMERCIALIZATION.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.01 <U>General</U>.
Subject to the terms and conditions of this Agreement, Prophase has the sole right to Commercialize Licensed Compound and Licensed Products
in the Field in the Territory; Prophase shall use Commercially Reasonable Efforts to conduct Development activities as set forth in the
Development Plan, as may be amended from time to time by mutual written agreement of the Parties. Prophase shall have the right to subcontract
any Development activities relating to the Licensed Compound and Licensed Products in the Field in the Territory, as deemed appropriate
in Prophase&rsquo;s reasonable discretion. Prophase has the right, but not the obligation, to directly consult or contract with Daryl
L. Thompson and/or GRDG, at Prophase&rsquo;s expense, in connection with Development of Licensed Compound and/or Licensed Product. For
the avoidance of doubt, it is understood by the Parties that intellectual property related to Licensed Compound that may be created,
made, developed, or otherwise invented by GRDG and which is funded by Global BioLife shall be owned by Global BioLife, and that all such
new intellectual property shall be Licensed IP under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.02 <U>Development
Plan.</U> The Development of Licensed Compound and the first Licensed Product for the United States shall be governed by a clinical Development
plan (&ldquo;Preliminary Development Plan&rdquo;), a draft of which is provided in Section 5.03.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.03 <U>Development
Plan.</U> The Parties have prepared a Development Plan, including anticipated timeline goals in connection with the Clinical Trials for
the first Licensed Product. This Development Plan may be amended by mutual written agreement based upon results of preclinical studies
or other Clinical Trial, including safety and effectiveness, guidance by the FDA, or upon agreement of the Parties:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Initiate
preclinical studies with respect to Development of a first Licensed Product within one year of the Effective Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Initiate
a Phase 1 Study in connection with Development of a first Licensed Product within 18 months of initiation of the preclinical studies;
provided that an IND for first Licensed Product is approved by FDA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Initiate
a Phase 2 Study in connection with Development of a first Licensed Product within 24 months of initiation of a first Phase 1 Study; provided
that the Phase 1 Study successfully established safety of the first Licensed Product;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Initiate
a Phase 3 Study in connection with Development of a first Licensed Product within 48 months of initiation of a first Phase 2 Study; provided
that the Phase 2 Study successfully established safety and effectiveness of the first Licensed Product;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Submit
NDA to FDA by January 4, 2027 or as soon as practicable thereafter, using Commercially Reasonable Efforts; provided that Phase 3 Study
is successfully completed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Market
first Licensed Product in the United States not later than 30 days after Regulatory Approval by FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.04 <U>Joint
Meetings</U>. The Parties shall establish semi-annual joint meetings to discuss in good faith and in reasonable detail Prophase&rsquo;s
and its Sublicencees&rsquo; activities and progress related to the Development of Licensed Compound and Licensed Products in the Territory
in accordance with the Development Plan.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>6. <U>INTELLECTUAL
PROPERTY</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.01 <U>Inventions;
Ownership</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Inventor
Assignment Obligation</U>. Each Party shall cause all employees, independent contractors, contract research organizations, consultants,
and others who perform activities for such Party under this Agreement to be under an obligation to assign (or, if such Party is unable
to cause such person or entity to agree to such assignment obligation despite such Party using Commercially Reasonable Efforts to negotiate
such assignment obligation, provide a license under) their rights in any Inventions and Intellectual Property Rights to such Party, except
where applicable Law requires otherwise and except in the case of governmental, not-for-profit, and public institutions which have standard
policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be obtained).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Ownership
and Disclosure Obligations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Subject
to the rights and licenses expressly granted under this Agreement, each Party shall retain all rights, title, and interests in, to and
under any and all Intellectual Property Rights that are owned by such Party prior to the Effective Date or independent of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Inventions
that directly relate to Licensed Compound or Licensed Product in the Field, whether patentable or not, that are made in the course of
performing activities under this Agreement, (a) by either Party, (b) jointly by both Parties, (c) by GRDG, (d) by a Prophase sublicensee,
or (e) jointly by any combination of the preceeding (a) &ndash; (d) shall be the joint property of Prophase and Global BioLife (&ldquo;<U>Joint
Inventions</U>&rdquo;). The Parties agree to keep each other informed of such Joint Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Prophase
and Global BioLife each agree to obtain the cooperation of their respective employees or obligated Third Parties that are inventors in
the preparation, filing, and prosecution of patent applications directed to any Inventions that may arise hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.02 <U>Prosecution
and Maintenance of Patent Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) At
the initiative of ProPhase or Licensor, the Parties shall consult in good faith with each other regarding the filing, prosecution, and
maintenance of all Licensed Patents. The Licensed Patents shall be diligently filed, prosecuted and maintained by Licensor using reputable
counsel. Licensor shall keep ProPhase reasonably informed with regard to the preparation, filing, prosecution, and maintenance of the
Licensed Patents, including by providing ProPhase (or its designee) copies of office actions issued from patent offices, proposed responses
to such office actions, and any other patent related filings, to be made to such patent authority in the Territory sufficiently in advance
of submitting such filings or responses so as to allow for a reasonable opportunity for ProPhase to review and comment thereon. Licensor
shall consider in good faith any such comments for incorporation into such draft. Licensor represents that during the Term that (a) all
Licensed Patents will be diligently prosecuted in the respective patent offices in the Territory in accordance with applicable laws,
rules and regulations, (b) all Licensed Patents will be filed and maintained properly and correctly, (c) Licensor will pay all applicable
fees on or before the due date for payment, and (d) all Licensed Patents will identify each and every inventor of the claims thereof
as determined in accordance with the laws of the jurisdiction in which such Patent is filed. Prophase shall reimburse Global BioLife
for reasonable attorney fees and patent office costs associated with the prosecution and maintenance of the Licensed Patents on a quarterly
basis commencing on September 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If,
at any time during the Term, the Parties may mutually agree that it is undesirable, as to one or more countries, to file, prosecute or
maintain any Licensed Patent, then Global BioLife shall have discretion to refrain from filing, prosecuting and/or maintaining any Licensed
Patent or permitting the Licensed Patent to lapse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Parties shall cooperate with each other and discuss, in good faith, the Patent Rights within the Licensed Patents Covering the Licensed
Compound and Licensed Products to enable Prophase to make filings with Regulatory Authorities, as required or allowed in connection with
(A) in the United States, the FDA&rsquo;s Orange Book and (B) outside the United States, under the national implementations of Article
10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents thereof. Global BioLife shall cooperate with Prophase&rsquo;s
reasonable requests in connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Parties shall cooperate in obtaining Patent Term Extensions pursuant to 35 U.S.C. &sect; 156 and foreign counterparts and equivalents
thereof, including supplementary protection certificates, to the extent such extensions are available with respect to the applicable
Patent Rights (&ldquo;<U>Extension Activities</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>7. <U>CONFIDENTIAL
INFORMATION.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.01 <U>Confidential
Information</U>. All Confidential Information of a Disclosing Party shall not be used by the other Party (the &ldquo;<U>Receiving Party</U>&rdquo;),
except in performing its obligations or exercising rights explicitly granted under this Agreement and shall be maintained in confidence
by the Receiving Party and shall not otherwise be disclosed by the Receiving Party to any Third Party, without the prior written consent
of the Disclosing Party with respect to such Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.02 The
obligation of confidentiality and non-use set forth in Section 7.01 shall not apply to any Confidential Information which: (a) was part
of the public domain prior to the Effective Date or which becomes a part of the public domain not due to some unauthorized act by or
omission of receiving Party after the Effective Date, (b) which is disclosed to Receiving Party by a third party who has the right to
make such disclosure, (c) was known by Receiving Party prior to the disclosure of such Confidential Information by Disclosing Party to
Receiving Party, as evidenced by the competent written records of Receiving Party maintained in the ordinary course of business, and
(d) was independently developed by Receiving Party without reliance on such Confidential Information, as evidenced by the competent written
records of Receiving Party maintained in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.03 The
Parties agree that the financial terms as set forth in this Agreement and the Memorandum of Understanding dated July 1, 2022, shall constitute
Confidential Information of the each Party, and shall be disclosed only to on a need-to-know basis, each Party&rsquo;s employees, directors,
officers, Affiliates, representatives, and agents subject to any disclosure obligation pursuant to SEC and FDA rules and regulations,
and any rules and regulations of similar authorities around the world. It is further understood by the Parties that the existence of
this Agreement and the Memorandum of Understanding is to be disclosed in a Press Release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.04 It
is further agreed that each Party may disclose Confidential Information of the Disclosing Party to the extent that such disclosure is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
the reasonable opinion of the Receiving Party&rsquo;s legal counsel, required to be disclosed pursuant to law, regulation or a valid
order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental
body of competent jurisdiction (other than a securities regulatory authority, which is addressed in Section 7.05); provided, that the
Receiving Party shall first have given prompt written notice (and to the extent possible, at least five (5) business days&rsquo; notice),
to the Disclosing Party and given the Disclosing Party a reasonable opportunity to take whatever action it deems necessary to protect
its Confidential Information. In the event that no protective order or other remedy is obtained, or the Disclosing Party waives compliance
with the terms of this Agreement, the Receiving Party shall furnish only that portion of Confidential Information which the Receiving
Party is advised by counsel is legally required to be disclosed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) made
by or on behalf of the receiving Party to the Regulatory Authorities as required by applicable laws, rules or regulations; provided,
that reasonable measures shall be taken to assure confidential treatment of such Confidential Information to the extent practicable and
consistent with applicable laws, rules and regulations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) made
by or on behalf of the Receiving Party to a patent authority, as may be reasonably necessary or useful for purposes of obtaining, defending
or enforcing a Patent in accordance with the terms of this Agreement; provided, that reasonable measures shall be taken to assure confidential
treatment of such Confidential Information, to the extent such protection is available;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) made
to its or its Affiliates&rsquo; financial and legal advisors who have a need to know such Disclosing Party&rsquo;s Confidential Information
and are either under professional codes of conduct giving rise to expectations of confidentiality and non-use or under written agreements
of confidentiality and non-use, in each case, at least as restrictive as those set forth in this Agreement; provided that the receiving
Party shall remain responsible for any failure by such financial and legal advisors, to treat such Confidential Information as required
under this <U>Section 7</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) made
by a Party, its Affiliates or its Sublicensees to potential or actual investors or acquirers as may be necessary in connection with their
evaluation of such potential or actual investment or acquisition; provided, that such persons shall be subject to obligations of confidentiality
and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use pursuant
to this <U>Section 7</U>; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) made
by a Party, its Affiliates or Sublicensees to its or their advisors, consultants, clinicians, vendors, service providers, contractors,
existing or prospective collaboration partners, licensees, sublicensees, or other third parties as may be necessary or useful in connection
with the Exploitation of the Licensed Products, or otherwise in connection with the performance of its obligations or exercise of its
rights as contemplated by this Agreement; provided, that such persons shall be subject to obligations of confidentiality and non-use
with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving
Party pursuant to this <U>Section 7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.05 The
Parties each acknowledge that the other Party (or its Affiliate) is a publicly traded company. Notwithstanding anything in this Agreement
to the contrary, each Party may (a) make such disclosures with respect to this Agreement as it determines are reasonably necessary to
comply with applicable legal requirements, laws, rules and regulations imposed by a securities regulatory authority; provided that the
disclosing Party shall seek confidential treatment of any disclosure of this Agreement, which such disclosure shall be reviewed by the
non-disclosing Party reasonably in advance of such disclosure to allow the non-disclosing Party to provide comments, which shall be considered
for redaction in good faith by the disclosing Party, and (b) disclose the terms and conditions of this Agreement to any person or entity
conducting due diligence into such Party and its businesses; provided that such person or entity is bound by obligations of confidentiality
and non-use no less restrictive than this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.06 Prophase
has the right, but not the obligation, to work with GRDG in the Development and Exploitation of Licensed Compound and Licensed Product.
Accordingly, it is accepted and agreed by the Parties that Confidential Information may be disclosed to GRDG without violation of this
Agreement. Global Biolife represents that Global Biolife and GRDG have executed a confidentiality agreement substantially similar to
that set forth herein.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>8. <U>INFRINGEMENT
OF LICENSED PATENT.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.01 In
the event a Party becomes aware that a third party is infringing on one or more of the Licensed Patents, the Party that becomes aware
of such infringement shall promptly notify the other Party to the Agreement in writing of such infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.02 With
respect to any infringing activity that involves the manufacture, use or sale by a Third Party of any product that is believed to and/or
infringe a Licensed Patent (&ldquo;Infringing <U>Product</U>&rdquo;), ProPhase shall have the sole right, but not obligation, to bring
suit to enforce any Licensed Patent against the infringer and/or to defend any declaratory judgment action with respect thereto (either
of which shall be considered as an &ldquo;<U>Action</U>&rdquo;) and, upon initiating any Action, shall keep Licensor reasonably informed
with regard to the status of such suit and related activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.03 Each
Party shall always have the right to be represented by counsel of its own selection at its own cost in any suit for infringement of the
Licensed Patent(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.04 Licensor
agrees to cooperate in the litigation with ProPhase at the reasonable request and at the sole expense of ProPhase, including, by giving
testimony and producing documents lawfully requested in the prosecution of any suit by ProPhase for infringement of the Licensed Patent(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.05 Any
recovery from such infringement suit shall be distributed to the Parties as follows: (a) first, reimbursement of the costs and expenses
incurred by or on behalf of ProPhase and then Global BioLife&rsquo;s expenses, if any, in connection with such Action; and (b) second,
any remaining recovery shall, to the extent the same pertains to an infringing activity that involves the manufacture, use or sale by
a third party of any Infringing Product, be treated as Net Revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.06 In
the event Prophase elects not to initiate an Action with respect to any commercially significant infringing activity that involves the
manufacture, use or sale by a Third Party of any Infringing Product, Global BioLife may initiate such Action at its sole expense. Prophase
shall have the right to participate in any such Action with counsel of its own choice at its own expense. All recoveries received by
Global BioLife from an Action shall be first applied to reimburse Global BioLife&rsquo;s and then Prophase&rsquo;s unreimbursed expenses,
including, without limitation, reasonable attorney&rsquo;s fees and court costs. Global BioLife is entitled to any remainder of the recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.07 Neither
Party shall settle an Action with an infringer without the consent of the other Party, such consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>9. <U>LIABILITY
AND INDEMNIFICATION.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.01 ProPhase
shall indemnify, defend and hold harmless Licensor and its directors, officers, and employees and their respective successors, heirs
and assigns (the &ldquo;<U>Licensor Indemnitees</U>&rdquo;), against any liability, damage, loss or expense (including reasonable attorneys&rsquo;
fees and expenses) incurred by or imposed upon the Licensor Indemnitees or any one of them in connection with any third party claims,
suits, actions, demands or judgments arising out of (a) the Exploitation of a Licensed Compound or Licensed Product by or on behalf of
ProPhase, (b) a wilful breach by Licensee of this Agreement, or (c) the gross negligence or wilful misconduct of a ProPhase Indemnitee
in connection with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.02 The
Indemnitees shall provide Prophase (&ldquo;Indemnitor&rdquo;) with prompt written notice of any claim, suit or action for which indemnification
is sought; provided that the failure of an Indemnitee so to notify Indemnitor will not relieve Indemnitor from liability for indemnification
only if and to the extent such failure materially compromises Indemnitor&rsquo;s defense of such claim, suit or action. Indemnitor agrees,
at its own expense, to provide attorneys reasonably acceptable to Licensor on behalf of the Licensor Indemnitees to defend against any
such claim, suit or action. The Indemnitees shall cooperate fully with Indemnitor in such defense, at Indemnitor&rsquo;s expense, and
will permit Indemnitor to conduct and control such defense and the disposition of any such claim, suit, or action; provided that (a)
Indemnitor shall not settle any such claim, suit or action that (i) admits any liability or wrongdoing on behalf of an Indemnitee, or
(ii) obligates an Indemnitee to take, or restricts an Indemnitee from taking, any action, in either case ((i) or (ii)), without the prior
written consent of Licensor on behalf of the Licensor Indemnitees, which consent shall not be unreasonably denied, and (b) any Indemnitee
shall have the right to retain its own counsel, at the expense of Indemnitor, if representation of such Indemnitee by the counsel retained
by Indemnitor would be inappropriate because of actual differences in the interests of such Indemnitee and any other Party represented
by such counsel. Indemnitor agrees to keep Licensor reasonably informed of the progress in the defense and disposition of such claim,
suit or action and to consult with Licensor with regard to any proposed settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.03 NEITHER
PARTY NOR ANY OF ITS AFFILIATES OR SUBLICENSEES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL
DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT,
NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY OUT OF THE TERMS OF THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY OR THE USE OF THE COMPOUND OR PRODUCT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>10. <U>TERM
AND TERMINATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.01 <U>Term</U>.
Unless earlier terminated pursuant to this <U>Section 10</U>, this Agreement shall commence on the Effective Date and expire automatically
on a country-by-country basis upon the last to occur of the expiration of the last-to-expire Licensed Patents (&ldquo;Term&rdquo;). Following
the expiration of the Term, and on a country-by-country basis, the License shall become non-exclusive, perpetual, fully-paid, unrestricted,
royalty-free and irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.02 <U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Termination
by Prophase for Convenience</U>. Prophase shall have the right to terminate this Agreement for any reason or for convenience in its sole
discretion: (i) on a Licensed Product-by-Licensed Product or a country-by-country basis or (ii) in its entirety, in either case ((i)
or (ii)) for convenience upon one hundred eighty (180) days prior written notice to Global BioLife. Prophase shall perform any obligations
owed to Global BioLife as of the date of said termination notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Termination
by Global BioLife</U>. Global BioLife shall have the right to terminate this Agreement only for uncured material breach by Prophase as
follows: if Global BioLife believes that the Prophase is in material breach of its obligations under this Agreement, then Global BioLife
may provide written notice to the Prophase setting forth a description of the asserted material breach. Prophase shall then have the
option to cure such asserted material breach within sixty (60) days after actual receipt of such written notice (or such longer period
as may be agreed by the Parties). If Prophase does not cure such breach by the end of the sixty (60) days period to the satisfaction
of Global BioLife after the other Party provides notice of such breach as above, then Global BioLife may then terminate the Agreement
immediately on written notice to Prophase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Challenging
Validity</U>. During the term of this Agreement, Prophase and its Affiliates (&ldquo;Challenging Party&rdquo;) shall not challenge the
validity or ownership of Licensed Patents (&ldquo;Patent Challenge&rdquo;) or knowingly assist a Third Party in a Patent Challenge. Global
BioLife at its sole and absolute option may terminate this Agreement upon written notice to Prophase, upon the commencement by Challenging
Party of a Patent Challenge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.03 <U>Effects
of Termination</U>. If this Agreement is terminated in its entirety by either Party, or on Licensed Product-by-Licensed Product or a
country-by-country basis, then with respect only to such Licensed Product or such country, as the case may be (it being understood that,
if this Agreement is terminated in its entirety, then all references below to &ldquo;terminated Licensed Product&rdquo; shall instead
be references to all Licensed Products, and &ldquo;the terminated countries&rdquo; shall instead be references to &ldquo;the Territory&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Any
Termination</U>. In the event of any termination of this Agreement and regardless of the terminating Party:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) all
rights and licenses granted by Global BioLife hereunder shall immediately terminate and be of no force or effect with respect to the
terminated Licensed Product in the terminated countries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) promptly
after the notice date of any such termination or otherwise after effective date of such termination, Prophase, at its sole cost, shall
commence winding down its Exploitation activities for the terminated Licensed Products in the terminated countries, and shall use good
faith efforts to complete any and all such wind-down Development and Commercialization activities within three (3) months after the notice
date or effective date of such termination, as applicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Prophase
may sell off its existing inventory of terminated Licensed Products for a period of six (6) months subject to, if applicable, the milestones
and royalty provisions of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) if
such termination is a termination of this Agreement in its entirety, each Party shall promptly return all Confidential Information of
the other Party that are not subject to a continuing license hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Termination
by Prophase</U>. In the event of a termination by Prophase:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) upon
written request by Global BioLife within thirty (30) days following such termination, unless prohibited by Regulatory Authority, Prophase
shall transition the conduct of any on-going Clinical Trials to Global BioLife;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) if
this Agreement is terminated in its entirety or as to a terminated Licensed Product on a country-by country or worldwide basis, Prophase
shall, at no cost to Global BioLife: (A) assign to Global BioLife or Global BioLife&rsquo;s designee all Regulatory Documentation that
is requested by Global BioLife and/or necessary for Global BioLife to Exploit such terminated Licensed Product in the terminated country
and (B) provide to Global BioLife or Global BioLife&rsquo;s designee a Right of Reference and right to use in the terminated country
all Regulatory Documentation that is necessary to Exploit, but not solely related to, such terminated Licensed Product in the terminated
country; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) if
termination is with respect to one or more Licensed Products other than on a worldwide basis, Prophase shall provide to Global BioLife
or Global BioLife&rsquo;s designee, at no expenses, a Right of Reference and right to use in the terminated country all Regulatory Documentation
necessary to Exploit the terminated Licensed Product in the terminated country.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>11. <U>REPRESENTATIONS
AND WARRANTIES BY PROPHASE.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
hereby represents and warrants to Licensor as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.01 ProPhase
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. ProPhase has been granted
all requisite power and authority to carry on its business and to own and operate its properties and assets. The execution, delivery
and performance of this Agreement have been duly authorized by ProPhase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.02 There
is no pending or, to ProPhase&rsquo;s Knowledge, threatened litigation involving ProPhase which would have any effect on this Agreement
or on ProPhase&rsquo;s ability to perform its obligations hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.03 There
is no indenture, contract, or agreement to which ProPhase is a party or by which ProPhase is bound which prohibits or would prohibit
the execution and delivery by ProPhase of this Agreement or the performance or observance by ProPhase of any term or condition of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>12. <U>REPRESENTATIONS
AND WARRANTIES BY LICENSOR.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor
hereby represents and warrants to ProPhase as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.01 Licensor
is a corporation duly organized, validly existing and in good standing under the laws of Nevada. Licensor has been granted all requisite
power and authority to carry on its business and to own and operate its properties and assets. The execution, delivery and performance
of this Agreement have been duly authorized by Licensor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.02 There
is no pending or, to Licensor&rsquo;s knowledge, threatened litigation involving Licensor which would have any effect on this Agreement
or on Licensor&rsquo;s ability to perform its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.03 To
Licensor&rsquo;s knowledge, there is no indenture, contract, or agreement to which Licensor is a party or by which Licensor is bound
which prohibits or would prohibit the execution and delivery by Licensor of this Agreement or the performance or observance by Licensor
of any term or condition of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.04 All
Licensed IP existing as of the Effective Date is solely and exclusively owned by Licensor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.05 To
Licensor&rsquo;s Knowledge, all Licensed Patents existing as of the Effective Date are subsisting and are not invalid or unenforceable,
in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.06 To
Licensor&rsquo;s Knowledge, the Licensed Patents existing as of the Effective Date (a) are being diligently prosecuted in the respective
patent offices in the Territory in accordance with applicable laws, rules and regulations, (b) have been filed and maintained properly
and correctly and all applicable fees have been paid on or before the due date for payment, and (c) identifies each and every inventor
of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Patent is issued or such application
is pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.07 To
Licensor&rsquo;s Knowledge, there are no claims, judgments, or settlements against, or amounts with respect thereto, owed by Licensor
or any of its Affiliates relating to the Licensed IP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.08 No
claim or litigation has been brought or, to Licensor&rsquo;s Knowledge, threatened by any person or entity alleging, that (a) the Licensed
Patents existing as of the Effective Date are invalid or unenforceable, or (b) the Licensed IP, or the disclosing, copying, making, assigning,
or licensing of the Licensed IP, or the Exploitation of the Licensed Compounds or Licensed Products as contemplated herein, does or will
violate, infringe, misappropriate or otherwise conflict or interfere with, any Patent or other intellectual property or proprietary right
of any person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.09 To
Licensor&rsquo;s Knowledge, the Exploitation of the Licensed Compound or Licensed IP does not violate, infringe, misappropriate, or otherwise
conflict or interfere with any Patent or other intellectual property or proprietary right of any person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10 To
Licensor&rsquo;s Knowledge, no person or entity is infringing or threatening to infringe or misappropriating or threatening to misappropriate
the Licensed IP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.11 To
Licensor&rsquo;s Knowledge, with respect to the pending patent applications included in the Licensed Patents existing as of the Effective
Date, Licensor and its Affiliates have presented all relevant references, documents, or information of which it and the inventors are
aware to the relevant patent examiner at the relevant patent office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.12 To
Licensor&rsquo;s Knowledge, no funding from any governmental entity of any kind was used in connection with development of any of the
intellectual property rights included in the scope of the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.13 To
Licensor&rsquo;s Knowledge the Licensed Compound has not been used in humans in any form on behalf of Licensor or its Affiliates prior
to the Effective Date.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>13. <U>COMPLIANCE.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party and its Affiliates (a) have complied and shall comply with all applicable laws, rules and regulations governing bribery, money
laundering, and other corrupt practices and behavior (including, as applicable, the U.S. Foreign Corrupt Practices Act and UK Bribery
Act) and (b) shall not, directly or indirectly, offer, give, pay, promise to pay, or authorize the payment of any bribes, kickbacks,
influence payments, or other unlawful or improper inducements to any person or entity in whatever form (including gifts, travel, entertainment,
contributions, or anything else of value).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>14. <U>NO
ASSIGNMENT.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
party shall assign this Agreement or any part thereof without the prior written consent of the other party, which consent shall not be
unreasonably withheld or delayed. Each party may, however, without such consent, assign or sell its rights under this Agreement (a) in
connection with the sale or transfer of all or substantially all of its assets to a Third Party; (b) in the event of a merger or consolidation
with a Third Party; or (c) to an Affiliate. No assignment shall relieve any party of responsibility for the performance of any accrued
obligation which such party has under this Agreement. Any assignment shall be contingent upon the assignee assuming in writing all of
the obligations of its assignor under this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>15. <U>USE
OF NAME; PUBLIC ANNOUNCEMENTS.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
the prior written consent of the other Party, neither ProPhase nor Licensor shall use the name of the other Party or any adaptation thereof
or of any employee of the other Party, unless such use is otherwise required by law, rule or regulation. Except as provided herein, Licensor
will not issue any public announcements about this Agreement without prior written approval of ProPhase. Notwithstanding the preceding,
it is agreed by the Parties that one or more Press Release may be published relating to this Agreement and that each Party shall provide
the other with an opportunity to review and revise such Press Releases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT>&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; text-transform: uppercase"><B>16. <U>MISCELLANEOUS.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.01 Neither
Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure
or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from events beyond
the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics,
quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts,
or other labor disturbances (whether involving the workforce of the non-performing Party or of any other person), acts of God or acts,
omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing
Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of
such force majeure event within thirty (30) days after such occurrence by giving written notice to the other Party stating the nature
of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall
be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts
to remedy its inability to perform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.02 If
any provision of this Agreement is determined to be invalid or void, the remaining provisions shall remain in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.03 Both
Parties irrevocably consent to first present any dispute related to this Agreement in writing to the other Party. Within two (2) months
of receipt of such notice, the Parties agree to attend a face-to-face meeting which shall include at least one individual from each Party
who is authorized to make decisions for and settle the dispute. Such a meeting shall be held at a location agreed upon by the Parties.
In the event that good faith negotiations are unsuccessful, the Parties shall present the dispute to non-binding mediation before a single
mediator in a location agreed upon by the Parties. The Party first initiating the dispute shall present a list of no less than five potential
mediators to the other Party and that Party shall promptly select one mediator therefrom. Should nonbinding mediation be unsuccessful,
as determined by the chosen mediator or either Party, the dispute may be presented to litigation in the federal or state courts of the
State of Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.04 This
Agreement is governed by the internal laws of the State of Texas, without regard and to the exclusion of Texas&rsquo; conflict of laws
rules. The United Nations Convention for the International Sale of Goods is excluded and shall not apply. The Parties hereby submit to
the sole and exclusive jurisdiction of, and waive any venue objections against, the state and federal courts located in the State of
Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.05 All
payments or notices required or permitted to be given under this Agreement shall be given in writing and shall be effective when either
personally delivered or deposited, postage prepaid, in the United States registered or certified mail, or sent via a recognized national
overnight delivery service (e.g., Federal Express or DHL), addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in">To Licensor:</TD>
    <TD>Global Biolife, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>1400 Broadfield Blvd., Suite 100</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Houston, TX 77084</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attention: Frank D. Heuszel</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Email: frank.heuszel@dssworld.com and </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>fheuszel@impactbiomedinc.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD>With copy to, which shall not constitute notice:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Remenick PLLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>1025 Thomas Jefferson Street, NW; Suite 175</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Washington, DC 20007</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attention: James Remenick</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>E-mail: jremenick@remenicklaw.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in">To ProPhase:</TD>
    <TD>ProPhase Labs, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>711 Stewart Ave, Suite 200</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Garden City, NY 11530</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attention: Ted Karkus</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>E-mail: karkus@prophaselabs.com</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>With copy to, which shall not constitute notice:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Reed Smith LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>599 Lexington Avenue, 22nd Floor</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>New York, NY 10022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attention: Herbert Kozlov</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>E-mail: hkozlov@reedsmith.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
such other address or addresses as either Party may hereafter specify by written notice to the other. Such notices and communications
shall be deemed effective on the date of delivery or fourteen (14) days after having been sent by registered or certified mail, whichever
is earlier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.06 This
Agreement (and the annexed appendices) constitute the entire Agreement between the Parties relating to the subject matter hereof, and
no variation, modification or waiver of any of the terms or conditions hereof shall be deemed valid unless made in writing and signed
by both Parties. This Agreement supersedes any and all prior agreements or understandings, whether oral or written, between the Parties
relating to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.07 No
waiver by either Party of any non-performance or violation by the other Party of any of the covenants, obligations or agreements of such
other Party hereunder shall be deemed to be a waiver of any subsequent violation or non-performance of the same or any other covenant,
agreement or obligation, nor shall forbearance by either Party be deemed to be a waiver by such Party of its rights or remedies with
respect to such violation or non-performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.08 The
descriptive headings contained in this Agreement are included for convenience and reference only and shall not be held to expand, modify
or aid in the interpretation, construction or meaning of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.09 It
is not the intent of the Parties to create a partnership or joint venture or to assume partnership responsibility or liability. The obligations
of the Parties shall be limited to those set out herein and such obligations shall be several and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.10 This
Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which will constitute one
and the same instrument. Each Party may execute this Agreement by facsimile transmission or in Portable Document Format sent by electronic
means. Signatures of authorized signatories of the Parties transmitted by facsimile or sent by electronic means in Portable Document
Format shall be deemed to be original signatures, shall be valid and binding, and, upon delivery, shall constitute due execution of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement effective as of the date and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: left">ProPhase Labs, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 44%"><I>/s/ Ted Karkus</I></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left"> Ted Karkus</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">CEO</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> 7/19/2022</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: left">Global BioLife, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><I>/s/ Frank D. Heuszel</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Frank D. Heuszel</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">CEO</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">July 18, 2022</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
Patents existing as of the Effective Date</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    appln. no.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    no.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing
    Date</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue
    Date</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017268240</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRI12018073634.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,024,728</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201780043667.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-Jan-2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17800008.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Dec-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19129214.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05-Sep-2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201817043242</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
    Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018-560998</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
    Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-012056</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending[</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Jan-2022</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; width: 8%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2018-7036052</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Dec-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018141590</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
    Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/156,021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,123,991</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-
May- 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Nov-18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/302,292</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,966,954</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Nov
- 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-Apr-21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US21/22538</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-May-2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
END **</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
Patent Application existing as of the Effective Date</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    appln. no.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    no.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing
    Date</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/530,956</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[pending]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    And Composition for Rendering Cancer Cells Susceptible to Treatment by Targeted Oncogenetic Drivers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Nov-2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 30.95pt; width: 119.05pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Labs Announces Licensing of New Investigational Cancer Compounds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confirms Quarterly Growth continues year-over-year</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Announces significant
progress being made in Genomics Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
to Host Live Webcast to Discuss Business Developments Today at 11:30 a.m. EST</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Garden
City, NY, July 21, 2022 </B>(GLOBE NEWSWIRE) --  ProPhase Labs, Inc. (NASDAQ: PRPH), a rapidly growing and diversified diagnostics,
genomics and biotech company, today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (&ldquo;PBIO&rdquo;), has executed
a license agreement with Global BioLife, Inc. (&ldquo;Global BioLife&rdquo;) for the Linebacker portfolio (LB-1 and LB-2), two patented
small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications. The Company also announced continued
year-over-year quarterly growth in revenues and earnings for Q2 2022 and projected year-over-year growth in Q3 2022. The Company is also
making significant progress with a potential strategic partner for ProPhase Precision Medicine, Inc., its wholly owned genomics subsidiary,
with plans to update shareholders further in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
is designed as an anti-cancer agent to be used as a co-therapy that targets PIM kinase receptors, a growth factor expressed in cancer.
In preclinical laboratory studies, LB-1 inhibited PIM, which could potentially slow the growth of the cancer and allow for better efficacy
of the co-therapy drug or treatment being used. Under the terms of the license agreement, PBIO has obtained exclusive rights worldwide
to develop and commercialize LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes,
diseases or symptoms including dementia and Alzheimer&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited to announce the second licensing agreement for ProPhase BioPharma (PBIO), our newly created subsidiary, whose goal is to
license, develop and commercialize novel drugs and compounds,&rdquo; commented Ted Karkus, ProPhase Lab&rsquo;s Chief Executive Officer.
&ldquo;We believe the Linebacker platform has multi-billion dollar potential in oncology as well as significant potential in other fields.
In the near term, we intend to initiate further development and studies of LB-1 as a potential cancer co-therapy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase&rsquo;s
initial focus for LB-1 is as a potential co-therapy for the following four drugs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TAXOL<SUP>&reg;
                                            </SUP>(Paclitaxel Injection)</I>: TAXOL is among the most affordable and best-selling chemotherapy
                                            drugs, with annual sales over $1 billion<SUP>1</SUP>.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Doxorubicin</I>:
                                            The global market for Doxorubicin is estimated at $1.1 billion in 2022<SUP>2</SUP>.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Topotecan</I>:
                                            Manufactured by GlaxoSmithKline as Hycamtin.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cisplatin</I>:
                                            Market revenue for Cisplatin was $326.0 million in 2019 and is projected to reach $547.0
                                            million in 2025, with a CAGR of 8.95% during 2020-2025<SUP>3</SUP>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Findings
From the Initial LB-1 Cell Line Proliferation in-vitro Studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
Co-Therapy with TAXOL</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            alone inhibited cell proliferation at 69.94% at 100uM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAXOL
                                            alone inhibited cell proliferation at 41.96% at 200nM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            and TAXOL combined inhibited cell proliferation at 75.5% (100uM of LB1 + 200nM Taxol)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
Co-Therapy with Doxorubicin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            alone inhibited cell proliferation at 69.66% at 100uM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doxorubicin
                                            alone inhibited cell proliferation at 51.6% at 2000nM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            and Doxorubicin combined inhibited cell proliferation at 86.95% (100uM of LB1 + 2000nM Doxorubicin)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
Co-Therapy with Topotecan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            alone inhibited cell proliferation at 69.54% at 100uM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Topotecan
                                            alone inhibited cell proliferation at 58.27% at 2000nM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            and Topotecan combined inhibited cell proliferation at 97.18% (100uM of LB1 + 2000nM Topotecan)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
Co-Therapy with Cisplatin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            alone inhibited cell proliferation at 72.33% at 100uM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cisplatin
                                            alone inhibited cell proliferation at 22.74% at 30uM</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
                                            and Cisplatin combined inhibited cell proliferation at 82.48% (100uM of LB1 + 30uM Cisplatin)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
preclinical studies of the Linebacker portfolio with each of the four drugs described above is currently being conducted by a major U.S.
university. ProPhase looks forward to the full results expected to be released in Q3 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Linebacker</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linebacker
is a modified polyphenol. Polyphenols are substances found in many nuts, vegetables and berries. Linebacker compounds are modified Myricetin,
which is a common plant-derived flavonoid. Myricetin exhibits a wide range of activities that include strong antioxidant, anticancer,
antidiabetic and anti-inflammatory activities. It displays activities that are related to the central nervous system. Anecdotal evidence
suggests that it may be beneficial to protect against diseases such as Parkinson&rsquo;s and Alzheimer&rsquo;s<SUP>4</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
is Mono-chlorinated Myricetin with a Chlorine atom substituted for the Hydroxy group at 5&rsquo; (position 5 on the B-ring). LB-2 is
Di-chlorinated Myricetin with Chlorine atoms substituted for the Hydroxy groups at 5&rsquo; and 7 (position 5 on the B-ring and position
7 on the A-ring).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
is being developed as a potential co-therapy to down-regulate PIM (proviral integration site for moloney murine leukemia virus) kinase,
which plays a key role as an oncogene in various cancers including myeloma, leukemia, prostate and breast cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy
drugs alone, like TAXOL (chemically known as paclitaxel), kill healthy cells alongside tumorous ones. LB-1 is being developed to focus
directly on the PIM expressions potentially rendering the cancer cell transcription and replication significantly less effective, so
that chemotherapy drugs such as TAXOL can effectively kill the existing tumor cells. LB-1 may also be developed as a potential standalone
post therapy to ensure cancer cells do not regenerate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-1
and LB-2 were initially developed by Global BioLife, Inc. in partnership with Global Research and Development Group Sciences (&ldquo;GRDG&rdquo;).
GRDG and Global BioLife created Linebacker, a multi-faceted therapeutic platform targeting metabolic, neurologic, cancer, and infectious
diseases, to mirror the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program that provides novel, multi-target
therapeutics for unmet physiological needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
BioPharma has also formed an advisory board with Daryl Thompson as its founding member. Daryl Thompson is President and Director of Scientific
Initiatives at GRDG and is a biochemist twice nominated for the Nobel Prize in 2015 and 2016 for his work in cutting-edge organic and
carbohydrate chemistry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
plans to work with Daryl Thompson and GRDG to continue the development of the Linebacker portfolio, as well as on other important compounds
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
compounds that ProPhase has licensed have enormous potential and represent years of scientific research. I truly believe that the Linebacker
portfolio represents a potential breakthrough in cancer research. I am thrilled to continue to work on these compounds with ProPhase
toward commercialization to ultimately improve the health and save the lives of so many,&rdquo; commented Daryl Thompson, President of
GRDG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
slide presentation dedicated to ProPhase BioPharma has been posted to the ProPhase Labs website. This is in addition to the company slide
presentation. It is located at https://ir.prophaselabs.com/company-information/presentations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Business Progress</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Diagnostics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase&rsquo;s
COVID-19 diagnostic testing business continues to experience year-over-year growth in revenues and earnings in Q2 2022 and is projecting
continued growth in Q3 2022. Year over year growth is attributed to a larger and more diverse customer base of specimen collection companies,
the acceleration of the BA.5 variant and the rise in overall COVID-19 cases across the country. Construction expanding the Company&rsquo;s
state-of-the-art CLIA lab in Garden City, NY is almost complete and will enable ProPhase to diversify with traditional clinical lab testing.
Plans are also being finalized for the build-out of a state-of-the-art genomics lab as part of the expansion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Precision Medicine</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continues to make significant progress with its ProPhase Precision Medicine subsidiary. The Company is actively negotiating a
strategic partnership with a multi-billion dollar genomics company to collaborate across different geographic markets and joint venture
opportunities focused on genomic sequencing, AI, sharing genomic data insights and related fields. The first initiative would include
a deal for lower cost Whole Genome Sequencing (WGS), which is expected to be finalized in the near future. The Company is also making
significant progress with major retailers to potentially provide WGS in retail stores by the fourth quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Update Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs&rsquo; CEO and Chairman of the Board of Directors, Ted Karkus, will host a live webcast today, Thursday, July 21, 2022, at 11:30
a.m. EST / 8:30 a.m. PST to review these latest developments at ProPhase Labs and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
access the call, please use the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thursday, July 21, 2022</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time:</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11:30 a.m. Eastern time, 8:30 a.m. Pacific time</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participants
can register for the webcast by navigating to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.renmarkfinancial.com/events/prophase-labs-reviews-latest-developments-2022-07-21-113000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-registration
required fields of information include name and email.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
ProPhase Labs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc. (Nasdaq: PRPH) (&ldquo;ProPhase&rdquo;) is a diversified diagnostics, genomics and biotech company that seeks to leverage
its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for
further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. The Company
also continues to operate a state-of-the-art contract manufacturing facility and the TK Supplements line of dietary supplements, distributed
in food, drug and mass stores throughout the country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA
certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19
testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen
and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing. Announced plans for expansion of lab to include traditional
clinical testing and genomics testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Precision Medicine, Inc., a wholly owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for
analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited
disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including
those that drive cancer progression. Currently selling Nebula Genomics whole genome sequencing products direct-to-consumer online, with
plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel
drugs and compounds beginning with Equivir and Equivir G. PBIO announced a second licensing agreement for two small molecule PIM kinase
inhibitors, Linebacker LB-1 and LB-2, in July 2022, with plans to pursue development and commercialization of LB-1 as a cancer co-therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products
and dietary supplements under the TK Supplements<SUP>&reg;</SUP> brand and Phamaloz contract manufacturing subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit www.ProPhaseLabs.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Global Research and Development Group</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
Research and Development Group (&ldquo;GRDG&rdquo;) is a scientific think tank and private research and development organization that
applies rapid analysis and problem-solving skills to quickly qualify, quantify, procure and test both applicable and accurate paradigms.
GRDG works with BARDA (Biological Advance Research Development Authority), DARPA (Defense Advanced Research Projects Agency) and the
Potomac Institute for Policy. It also has partnerships with major private sector research organizations including Charles River Laboratories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Global BioLife, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&ldquo;Global BioLife&rdquo;) is a wholly owned subsidiary of DSS, Inc. Global BioLife strives to leverage its scientific
know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into
the scientific expertise of GRDG Sciences, LLC, Global BioLife pledges to undertake a concerted effort in the R&amp;D, drug discovery
and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information
on Global BioLife visit http://impbio.com/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including statements
regarding our plans to develop Linebacker LB-1 and LB2, our ability to negotiate a strategic partnership for ProPhase Precision Medicine,
Inc., to reduce costs for its WGS products and services and to expand into retail, our financial projections for Q2 and Q3 2022, our
plans to expand our lab to include traditional clinical testing and genomics testing, to sell our whole genome sequencing products in
food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research. Management believes that these
forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.
These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, our ability
to secure or maintain proprietary patent protection for products and technologies we develop or license, challenges relating to, entering
into, and growing new business lines, general economic conditions, consumer demand for our products and services, the competitive environment,
and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings.
The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are
cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any
forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&reg;
</SUP>All brand names and trademarks are the property of respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>References:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">https://videocast.nih.gov/watch=35576#:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">:text=Taxol%20is%20among%20the%20most,annual%</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">20sales%20over%20%241%20billion</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.reportlinker.com/p06031392/Global-Doxorubicin-Industry.html?utm_source=GNW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">https://www.marketwatch.com/press-release/cisplatin-market-size-in-2022-top-countries-data-competitive-landscape-</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">corporate-strategy-share-industry-analysis-by-top-manufactures-growth-insights-and-forecasts-to-2029-128-report-pages-</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2022-06-07</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772053/</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Media Relations and Institutional Investor Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267-880-1111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investorrelations@prophaselabs.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Retail Investor Relations Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renmark
Financial Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Boidman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514-939-3989</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jboidman@renmarkfinancial.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ") @<# 2(  A$! Q$!_\0
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M?_(+MO\ KO\ ^RFNJKE?'?\ R"[;_KO_ .RFN',O]TJ>GZHRK?PV8?@L?\5
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MI>)ACQ%>?[P/Z"NJ\%:>L&F->LH\R=B >X4<8_/->'AJ4ZF+J4HNR=[ORO\
MKL<L(MU'%&,/ VH^7GS[?=C[N3_/%==H-G+8:-!;S+MD7.X9SW-:54-:O?L&
MD7-P#AU3"?[QX%>Y2P5#!WJPOHN_S.J-.-/WD<UXG\32+*]A8.5VG$LJGG/H
M*9X:\+QW4*W^H LC\QQ'N/4URUI ;R_A@).99 I/?DUZ]&BQ1K&@PJ@  =A7
MG8&+Q]:5>MJELNAC27M9.4B.&TMK=-D,$4:^BH!5._T+3M1C82VZ*Y'$B#:P
M_&M*BO=E2IRCRRBFO0ZG%-6:/,)TO_"^KLD4I##D,/NR+[BN^T75XM8LA,@"
MR+Q)'G[I_P *R/&]F)=+CN@/FA?!/LW'\\5SOA*^:TUR*//[N?\ =L/?M^O\
MZ\&E4E@,9["_N2_"_P#P=#E3=*IR]&>E5YUXU_Y#_P#VQ7^M>BUYUXU_Y#__
M &Q7^M=F=?[K\U^IIB?@-KP(/^)=='_IJ/Y"NKKS30]3U73X)!86OG1,^6_=
MEL''J*USXFU]AA-*PW_7)S6.!Q]*GAXPDG=>3)I58J"3.TK@O&.LQWDR6-NP
M:.([G8="WI^%%PWBK5QY3P2PQGJ OEC\<\U;TSP0$<2:C,' _P"64?0_4T8F
MM7QD?8T(-)[MZ!.4JBY8HI^#=(>>\&H2KB&+.S/\3?\ UJ[T]#21QI#&L<:!
M$48"J, "E/0UZ.#PL<+2]FM>_J;4X*$;'CK'%PQ/0/\ UKL%BN_%TY/F-;Z7
M$=JC'+D=_K_*N.E_US_[QKU?2+5;/2+6!!C;&"?J>3^IKY_*J/MISA)^[NUW
M[+T.2A'F;3V,V/P=I"(%:*20_P!YI#G]*QM>\(1VEJ]W8.Y5!EXFY./4&NXI
M" P(/(/!KW:N78:I!Q4$O-'3*C!JUCRG1]4ETF_2="2A.)$SPRUZLK!T#*<@
MC(->0WT'V74+FW[1RL@_ UZ?H4AET*Q9CD^2H_(8_I7F9)4DI3H2Z?YV9CAF
M[N++5W(T5G/(APR1LP^H%<CI/AN75PNHZQ-(XD&Y$SR1[^@]A7:45[%;"PKS
MC*IJETZ7[LZ)04FFS-3P_I*+M&GP$>ZY/YFL37?"5LUJ]SIZ>5*@+&,'*L/;
MT-=;12JX*A5@X.*^X)4XR5K'F?AK6)--U%(RQ-O,P5U)X!/&ZO3*\@OD$6HW
M*)PJRL!CZUZW;N9+:)SU9 3^5>9DE65IT9/X=OQ_R,<,WK%]#/U_5/[)TMYU
MP96.R,'^\>]<?X;T@:Y>S75\[21QD%LGEV/J?PK6\>%OLEF!]W>V?K@8_K5?
MP/J$,1GLI'"O(P://\78C^53B9QJYC&E5^%=.E["FU*LHRV.I&D::(_+^PV^
MWT\L5R^J^%(TU>S-HA%M-(%D0<[.Y_ BNUHKU*^"HUHJ,HK3R-Y4XR5FA%4*
MH51@ 8 %9^M:M'H]@9V&Z1OEC3/WC_A6C7G7C.]:XUKR ?DMU"@>YY/]/RJ,
MQQ+PU!RCN]$35GR1NBE;QWOB36%224L[\LQZ(O? _I7H.GZ'I^FQJL-NA<=9
M'&6/XUB>!;0)97%V1\TC[!] /\3^E=97-E6%BJ2KU-92UNR*$%R\SW95NM-L
M[V,I<6T;CU*\CZ&O/=9TZ?PYJJ/;2L$;YX9!U'L:],KFO&\(DT1),<QR@Y]B
M"/\ "KS3#0G1=5*THZW'6@G&_5%WP]K(UBPW/@7$?RR =_?\:*X_PA=_9M=1
M"<),C*?P&?Z45IEN*=>@I3>JT95&?-&[/2****] U"BBB@ HHHH **** "BB
ML#Q7K@T?3"L3?Z5."L?^R.[5<(.<E&.[(J5(TX.<MD<?X[U=M3U)=.MFW16V
M=V#PS8Y_(#^=<9:7TVF:A!>6[8EA<,/?V/L:ZC2]-V>'M5UF<'"Q-##GNS<$
M_AG^=<=+7T>&C!1=);+3_,^/QLZCFJTM&]5Y*^A] :9J,&K:;!?6[9CE7(]C
MW'X&K=>1?#[Q*-+U Z;=/BUNF&PD\(_3\CP/RKUVO"Q6'="HX].A]/@<6L31
M4^O7U"BBBN8[ KE?'?\ R"[;_KO_ .RFNJKE/'9_XEMJ/^FW]#7#F7^Z3]/U
M1E6_ALQ?!?\ R'Q_UR;^E>BUYQX,./$"#UC85Z/7-DG^Z_-_H1AO@"BBBO7.
M@**** /,/%/_ ",=W]5_]!%=UX:&/#ME_N?U-<+XI_Y&.[^J_P#H(KNO#?\
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M8OJ:]%(K*RAE((/<&EKK- HHHH **** "J.M?\@*_P#^O>3_ -!-7JHZU_R
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MVS[9X'X"MVBBL)SE-WD[G33I0IKE@DEY!1114EA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>prph-20220619.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2DabP9z5Z8qekhvWB0bRlazyUmrlpNZyamnkcGsdAK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:PRPH="http://prophaselabs.com/20220619" elementFormDefault="qualified" targetNamespace="http://prophaselabs.com/20220619">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://prophaselabs.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="prph-20220619_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="prph-20220619_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>prph-20220619_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>prph-20220619_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://prophaselabs.com/role/Cover" xlink:href="prph-20220619.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://prophaselabs.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139819133353776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 19,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-21617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROPHASE
LABS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000868278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">23-2577138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">711
                                            Stewart Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Garden
    City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">345-0919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRPH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prph-20220619.xsd" xlink:type="simple"/>
    <context id="From2022-06-19to2022-06-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000868278</identifier>
        </entity>
        <period>
            <startDate>2022-06-19</startDate>
            <endDate>2022-06-19</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-06-19to2022-06-19">0000868278</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-06-19to2022-06-19">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-06-19to2022-06-19">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-06-19to2022-06-19">2022-06-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-06-19to2022-06-19">PROPHASE LABS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-06-19to2022-06-19">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-06-19to2022-06-19">000-21617</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-06-19to2022-06-19">23-2577138</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-06-19to2022-06-19">711                                             Stewart Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-06-19to2022-06-19">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-06-19to2022-06-19">Garden     City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-06-19to2022-06-19">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-06-19to2022-06-19">11530</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-06-19to2022-06-19">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-06-19to2022-06-19">345-0919</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-06-19to2022-06-19">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-06-19to2022-06-19">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-06-19to2022-06-19">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-06-19to2022-06-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-06-19to2022-06-19">Common     Stock, par value $0.0005</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-06-19to2022-06-19">PRPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-06-19to2022-06-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-06-19to2022-06-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M;T3U5 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !O1/54G6'X]^X    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !O1/54F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( &]$]53JJ0P&9P0  $L1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !O1/54GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( &]$]527BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( &]$]52JQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !O1/54)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !O1/5499!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://prophaselabs.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex99-1.htm</File>
    <File>prph-20220619.xsd</File>
    <File>prph-20220619_lab.xml</File>
    <File>prph-20220619_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prph-20220619_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prph-20220619_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prph-20220619.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "PRPH",
   "nsuri": "http://prophaselabs.com/20220619",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-06-19to2022-06-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://prophaselabs.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-06-19to2022-06-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-22-019965-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-019965-xbrl.zip
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M0& XF_&6;NGTK,>/WF/;=/;J-O=-1]+FU,GK'?2W=SS;/])D#XL79ES0VHT
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M(%,9=VI0N]!;D!,EQ'&B1A&@..&<^:,(+D2Q<1S&=@<@D^G9-0DD\^E<Z+*
M_XEL[[*0>6]D:J?-6F XM#M3=F@(UJH&!))[>R[ J(, .0<P:MW"+L(H,L"+
MS!YU7C1Q5XGCN@17;T_^$DWD)8K;T,2L&J/WHVNT1;6GQ3: &CI::C4AVL0U
MKF-2*R/ME6>T/?D1@(ZFTQ93A^"0.H)F >3L6G;_V#LMR?PMDMEQT&?9V.
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MLJ*D1K1FD)S([K3VG58BC:/)INU5N) +="Z/*AOIM"ZJVE,]1RMU=5X4:VK
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M^#/3*$04VPDRFNJI8G@?L@<9]ZVJ.>J.3.,Z^@TG'3)\3E)E*4<G+44MT41
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MH95PZ27Z*A]4MW/ .L9<8V7'(F7GC6VJIZ/9D;I" YT2HQ#ZME0*B:$<5O
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M$CM&7D)62<W,]#N].L%+=I<N]9KX@9J+CJ$@E89!I$Q<^-+-\JC&V K$R53
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MF\SS&'.*EZ'>;8%V]=MLXVWO\J3WZR$;7 Q>;[889YHG,H#Q)B"ID;-Y'+
M2$:GP/L"/_-)#'0$3-YJ-B:.W_&RD529\%&Z$\FU@+J(>*P$"5@V!4*20%7S
MJ0KA&6H>PV_3?)1*&%;#'<4<CR5^T!%W$_TI#/[*U?/!\=F[GS1]A.G"I4Q<
M"S_/1-!L<!:2"2$8!]DDD(#!& 1U\RI4([ ?8,QS.18W1ES^THT-KU[#?.%E
M 5.,N'\%AD>B=#96H51LX_S8Z]*:X<,V3"2;*Y;P#+D7)I)&/ Q9I$*862C8
MX.P-NY(Q+DO&Y#,HG9J9560J#(_W2Y@+][4"1HSR,),)# #S@&T1.;QT&"&
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M9$X4A):FQ]R'WX"429!*83 @!O.<=K-Q%@/]"C^4,1!SR$(^4D"S2B^ >/-
MXD)(4EBVA[OA:2T@3DEB,@^#DMZ!6M-0S8G2[+/!#\*?W+*  ^$RN 3Y8"0R
M8&(FQLA'/NAW=W&YS$#GX$N!&-."9R0-C;&&[Z3-?HN!QND6& >,='O_+1$*
M0AED+HE:-<JXQ'<NKOT0S 4P)"BP NRF=!B XRW(S@B,!4$S!F40">W# F$7
MV9+<+&1L.4&8A%DM<'$\#GD4F=<9R%3 #J6XG'01P29%1E9%(L+OM0@YOMYT
M$0=:(04U&ROOD3',/,"W$-#J)*=A>N'?4P&4IW_2*<K_U#UQS>A?:_I&._\.
M% 42&2F.^"<K=1R13BI T066:LE>*53_DK8H[ FV@>0,*EOE&B3Z'-C.1_*[
M88B _H"[)@JX6J)^:#8L8[3>0]TQ:,20V"YUWYI(1<N:%>9Z-!+8$/[_A>NK
M/&TM668% ?:G4HS9*5DWR&GOD--)ZA2O!O@YE#";6X8*, .L/B*F)2O"&\DP
M1%T9@%KDNJ)E09RIV%>AFBQ03LX%6"X\O<,PP8M)(X(I& :ID8"%:D0Y F\.
MK1RX@?8*!"/<"'K5J=*@="[H%5DYB8QO9$.Z9 -8T5<*M;9]D_6EZWJSI2-5
M1Z:@BVF+0[@4W$AB.J/RTEM[66HF)_C!F@Z-FS%&=B3..:SMNUF]M</>\?DI
MZY^>GP]Z)R=G;U_]_*3SA'Z^'/3Z[F?[?!>[[G1^- _XC%#1[4 1+')X\>EO
M$<S[#.T:]\I@>$PG'0U//GTLN[!.>WM7QAB2'YZ\N)>![F_W_G&PMW]0;M_G
M3O"A(P!G+X:]_WUW?G3YV^#%3UI,GMO$X4?^=[2%-VX,.%BM&;\&?746HU,'
MRF'S:.OL!<P(AR?^C11P)O)IA($C/@:V#?@('%+R]D4*,P-U@>SK3\$.L]S]
M:?,AGF]9[R^.<W3\>(@: <B/_=!E5G/1>KMF]NVE3=H:7A!5?E4*_WR2_CYI
M^$1=*YV/T&\GJOLTHL'@PL3$;4#670EC[%7&1/+%W%%$AAUX>S]TVP4IH1F#
M00HBJ>U'25(%(7R[%#!4:!J @?<9^_^&QSDZYKF&W1TMV*N07ZO+"&3(+R".
M!%H>KQ<^CS(9/[*-_1YE15^FZ-%\EJ1X8\2#C6^2F"B&8W.@DQ]VMO?:'195
M14/W@#0<R) RX@G.#+B)_I3]L/MTO]WYM%DLC;Z]Z]0=Z_=>7:#K\ZQ]L/LC
M"W*-NA2NZ'AX&<FGG;OD$_R%EN7]VLAM,*I6;JG]I8P#@0_P'L#^6FD]_Y?G
ML9?H;!ZR 9^(YW#[7[D IQ!N8YYGJZ:.3L[^[29QP_C=PRSI" P7H8O?'8?@
M)[-N>Q>6G*I0!F@@?XJ9;L?ST9E.4IB+^U16GQ06_#(UEY)GA3Q9?O.A&-,=
M)RN<@_)UW22'HRUX%RM>RPBH]\H;">  F$U"[[+J-NS1] ;+;Y&HHWS68'GT
MRMYLX>:8_?@2U%@?A_R++*&V'O/1\8N7F-"*)VFS\5*KB+R-,QM1H#A"'P-2
M&-O"*%DHQ^!B9$:4>C.9:<4N302IUJ4C-0\*F:1,7WE#&]\A]6;<U+JN:1W,
M60=SOA#C?(HER4,5BTH^T4?QF"Q)1O!V]P[:!T]_I+*=3B=_\^VY0&L:NK=I
MDIA]"")ZVFT?[!$1;7<Z\9J('C,1?88@ @?91(I]%8VH*N!#!+6_VP8O=X-$
MDDGX==E_&^)B0WZMPLTOX^2NS;G/,>>6(K8U7=G:J%O+TF]1EGZL4;>WMS;J
MO@L:J@C;AR"EW6Z[L.S6IMWC)J7/,^VJN=2/-O">[5$>8X6%AR9>9<BUH?=-
M3/^.N%V9F*WINM9FWEJN?HMR]6/-O-UU[.[[H*%"U#Z(D?>LO;V_MO*^#TKZ
MS ">H[^/M_$.]MO=9W?:>,6 :POOFYC^:@NO4E!5TW6M+;RU3/T69>I'*>;]
M[?;.SO=IX7WK=<F%9'R(?=_>;N\;RW[G.]OVM>CX*'.LK$S^^)#;=OOI"G,,
M":P<;FV,?1/3[P6!-%!FB)]4P@94>F#O1!PANXWJS^U59<,D0B'X6HZPT66D
M9@+KUOU<:Q%GX<*V_&.3=$YU[*,%X[#^/Y5FO[4OV\U&'AMTEVS1+AN10Z6N
MJ)ESSC75OM,C<Z! +=(\S!!V)2D*XT<(G1!BNWQ0Q0"I[4;5G,X0M6ND\JS9
M*$FIUN6Q7P&(ZR%T0K$9!& "7*@"@ZF4J'"13$6L0F#!XC-<H@6!$F2< -C&
MB"6 #!8AJ$Z<9_"PF9B(#'LR+023T!I$2;LJ1 H4 AJO>.B;A9:^ .V 4#@$
M2"(-3$H4@6I!7)S,"V I,[AV'/*9BI4,VN5M( %(->%-B/S!-(\G L43]S,Y
M TD'<S*(3X2Y(1#01Q&B% C!:QEPQ!;!'RSB1[.!/P22CP0"'1'<":*Z+ &!
ME&.WV5F&*!TPTT5ZZYFX5 <*8L478JMI$+>QT#.5IRQ=I)F(VJP7"S]0&7PC
M9K .F$NSD>:3B4@SMX ,7CF*4O@3B[%$O <<%;1Q!D*0\0F7<9J5*"5I#J^3
MIVS ]15\H^("U6$EV @U^CR]V>A3-_JNN=0LD(7> *5[_C146L9$/R7)N[8M
M\Z4  TQ%AD-EAAAD!;#!ZT6@U34A;.4)!6/M7K.-1*5D!;!=I@QXQK&'?5^;
M;0.*(]-FXT2^;P)+CT\__/QT:0)(@?MW3\, ?=DOFXU]]VW/3K*V^_O)_67;
MZ_ZR1]Y?MA:)'["[ZCKQ0I8;[\>"#CDDN)60- A;IN:QI\4D1[.!<.$V0,//
MI";DHTQ,K-L-LM%T$D<*XSX+%N4DCD.17XE(<@:WY.FF194KS"MKJ+ KN /<
M>&&1ZQ!]:2(H?,1F7$LT38Q%5$4KBQ:P D3#= ]IH?4!EF%FT3B _< "L3<^
M-BE=F^GWEW!0+!(8$@ELG+P2MF)^ ^%24#:#?WX5 ]4A*20%(LMF"T@'7.VI
MX&$V75#DQPPS2='0SO)(:203&#=M%W!+-VD=*)HPF1 )3X.9BG"81I<C:5M
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MJ%0/)^6!/G5?U"/8FMOXZOUW_SX[\;H'E9.78!(F%#9RS%4>J(?1K.L$1L?
MQ=WG]*P^\ >+=RKG_90 F/ M&E?V2*%5Y_W\@>,39O/2D]"+R[0<Y>[P!A9B
MF,"<9A(I+>SA4J BX&4JL%#8"#4+VAF)\.%EQ93\,@C55H_@P2H49V#<]T7H
MRN&L47_<:^]2))U;7Q-_J26=OD0SY&#;%V_5IX2]/7')J*H\1E^/]4&9@)%G
M'@SOE!L/-RL/-BHWB0+QGAIC.L'C.F/]\[,>G@=#A^+1B5W,'=AECD,B2&U<
M3BAL"'^.D4X1$\!VH6$Q+6%/W[+%^YGF3KJRZLDSCBC:S<: G"0L@;!144+8
M!T\93ZDH?>51+L/ 4SFY0YS=6D-Q;!*.3A%J77A.]#XP>OQ(U>U[\L([Z[SP
M.B^\UE6TBKK/OS2#;A\G5_>U/0(*HYB..T5PR<:)^)5XSSF"&)-^STF!E:.>
M;I]4Z#*/L9@HBD5C412J^!O'$9;))+[ZD*5"?SKOE^(WH3TE3CBC(Y#CL<!J
M;;@!DRS)%)YACC4PYMF?2L*78*]AF+'94 G&E?+85#M2BA>4.CS6/H^E1E7!
MO%NL=]:B,PUQ$>[[@&<<[)+4'-UFHEZF4M(>ZT2O9"QUFKD#G/  JCF=5V>+
M.?&TS4#0L3\:7/<YU9G"];]/L;*!C@$63F?BLS=^?W6YZ4Z^D[?*QTOC9,59
MBZO.DF3F*$G8ECMIP!2Y:Y%Q&6(Q!19L5A+=-HG%8&+&(,;KP @"/95B*M$5
MV<-(]L1,M'WJ7=C^.*0"K.*R/*:SV?C-'-W9AVVM^[H>P>Z4*A6C@Z[JM'_Z
MSK0X3;G4$2^=-<HLP@\N(0@C5X_&(Z=H2L</400:HXWVY.J @SLUG.8ZI4]+
MIR"WBB.K05#9,ZO9%GM6G&$]@)_I2(>9%',;04<9B%7<U?.OJTD$BG:27YQ5
MCI+%4O3:;M;C(+FA@EWV?>$\>! $+9900Q(>=GKCJ+E*Y/C[/&ON^-W%R>E%
MU:_\^-5:7_!@Y\<;K?#H[MYLAJ_\#IW*0W,<PI/E3M<[^E?!SRL]T)4'DB28
M9(@G=N@N/6WYD!+SNZ(7=>>>>U%/0%Z4% 0.\?W-^GZ-Z)4B<D7_\9?<EWM=
M(7Q=@XT@?634SRFH,*'!U(4[6E6UQ'U*-./O5S6(5]IVZR^M:C/] 4=6D.!_
M9"G6!J&W,)&X@T4LU9DEX#C$?"8GQFW,5'TUC$O"SN?S-GBGZ)"BEQ9C!0%E
M8C&#D*5;+D/K88K6,P95ZAE;RJO:4GBFU;;7V?>VNUZWN]/I=&K[;NI.SUIX
MAH)-YJ39T."I2UU$ - @KYA)10=GS".3JQ 1.,MKL_>KK\+V>2^Y*'5?TR/8
MF64?V):A;[SE8(;]=<@&%X/7FT5)>9GQ-67EIM35)?VP4[M,_,)015"1NGXD
M-B!/RP C5J&E0EQ1M"L4F.R<P"S082TRDJG0,^F;,*H+@LTI;#<Q8;LR?FB#
M@[8VW+21V"JT-(\PJ$:SP#PBS+F8&@481S9].2(?C+*.S88[!KZL<*O&]I8B
MO&YJU7PGK2&"J?HY!EAM)!4KE-VB6I6>J2+'ZS*CU8>!QXAAQ*5'JD28P.SM
M7"A>I[F/C>#NZ%%*JH*]%LIL4>29A[^PRSP!W].$#^@T4A"F@109QVF6W[6P
M7=REQJF6=*Q4T**F&),=Y^#/VGBDK1'$7&TU1UU;!JF] EU1/6/8'#LLD)NP
MVVJ."#YEJ@$)P=W9@A_&Q$!LI!4']M&:TQ5%3K]2[T'496L^"O8E8 +#UV"4
MHK=&TJ)@"LP.E,QPBZ(1= )8&+G4GW**@'-3Z[ QZ%]L%L]#"_>R=W'I]=6_
MO6VVX;AJL\WZ6I*+B+SC?MULV!M;9>"L\I+*WI$Q1?%R'7--N!89[<&80O8$
M,=->/0"QK7UY= :YC#T_1%[1/)$&,P(DD6D8PA]&*EALR2C"C,F"ED7,3J]=
MQ.8=WI 4,/!"P>T70P_>12D_>G$,<\6&&5.'CK,M*B%P\Z@.0Q7V4D5VP1:Y
MC74/P0D6,M,]H[8\\<G]]4_7=13K.HKO6HW4=N+O*YOX1#5H\M=I)7]=R$*&
MMFU,+8,X&<(F2K28"A"W,X$=DE-E[4H.$G;Q-]Z#^5WM3-DE<Q -)^SE-4:K
M#Q95I%*\"-._)V][QCPDVU6-,D[P>V.XJ,B;NVEA &@JPH0D?4"](0L$ZH.7
M1:9<@$US@;..,VRH!FL:)T-WP1+@315H05B:>&6_*D8KTN-D#8)"3,#B%BT[
M<XZ6J* >-UP06@A1;LO?*RO&$DF5VMZ4 )&<7(.)2Y13^7V_P(I+11CB M^*
M$=C7)HN/^W&7=P##(*I<:CT#$$2>\PQ@/T,B!DS%5]JV\!'L#EMWX^7)FTUG
M\=*KJW@!%6ND0*Q#"\<BVU7K&PKGHK;\57.YMJ*]U/G @^.S=YL?+1SF/'7M
MJ"[0:KJXR+ZL-O018]SJ<(+!J$6Y@&(P5]D^J9& =X.%SZ9>Y/2O7,ZDJ4QV
MGU^!$0HSAM\YPP]\0X$T5TZ$<> E\NG,).= Y1'6&%M'U> M&# 0]/,(-8T2
MW97V0\(Q<"WNR,,V64.Y;)I>P4))KM-<?-SJS;"$ZV:Q#0K$DS5W?'7NH(("
M[+$*A,\#TUU7*=YW<JQ*[/1Y*091B2/8+[%RC#Y2_YZ5Z>^&_2)L8_O[?*P0
M=S+<^$LKXA0@;D&7K0AN$&K=3UI,GAOD.O"HC,L5,%@?<(#Z^ZZP2:7\KK;;
M^&BHL"AX-((%8TZNTE'&,]"[MA(&]]8'N6AQXVZ6(6K;*5VV:-RTWQ!8SE+;
M>MN_TO1?HK5,?3>5_$Z+S7!7&:;Z'%V<VX;+^N[4XT@EE$F>CX*LJ?M:'\&.
MF7UJ-CZ +;0*4LCD?BJ  QDH_RN6<?C+B$\YPP2%K@Z]A&M!(":NOQ_\/A#O
MH+!10KOH*#C*J4R=-!Z!,O=2%<Y(+2/8%MF8(.;]*U )?^7PGL:+%GX@SY1@
MYWP$RW(Q:3926 *?$!08]JX910'7X$P3CB'0290ZM"0$+; %VL>]BY,>VS@N
M48$L'E%)X]77ULO!G047>P'^ Z$2L8V/QC':= F:9F.@,MA&'_P1BYI*NFN
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M=/;S&* R??08"'49!1@RH'8*YM4#S$-%O0<E9Z.<=OKC^$9893[0YH!R\?9
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M'I#;PA7W6B-R!^')QO!.D4C+Q0! +$-S+\CVBK&:S80SL7A.WAM E%][@(_
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MVO"A:JZX(CC%/W7NP"ST2&W7-P#OANNGP0$DJCG9TBAI7:L5X1YAQ ;,YR<
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M)0>PV29&$P5$BMT90$@M1J7:SPO:9?:(>I%5_NX0V$!([OAU[4[3VEO;5FU
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M."UK+FAT;5!+ 0(4 Q0    ( &]$]53R9I2M*P,  +<+   1
M  "  >>B  !P<G!H+3(P,C(P-C$Y+GAS9%!+ 0(4 Q0    ( &]$]53*"P04
M_@H  ("&   5              "  4&F  !P<G!H+3(P,C(P-C$Y7VQA8BYX
M;6Q02P$"% ,4    " !O1/54L^3;@UD'  #=5P  %0              @ %R
ML0  <')P:"TR,#(R,#8Q.5]P<F4N>&UL4$L%!@     &  8 ;@$  /ZX
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
